Abstract
Background and Objectives. We explored the predictive value on therapy outcome of an early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomography ( 18F-FDG-PET) scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease. Design and Methods. One hundred and eight patients with newly-diagnosed Hodgkin's disease in stage IIA with adverse prognostic factors, or in stage IIB through IVB, were re-staged with FDG-PET after two cycles of ABVD (PET-2). The end-point of the study was the predictive value of PET-2 on 2-year progression-free survival and 2-year failure-free survival. No treatment variation based only on PET-2 results was allowed. Results. Eighty-eight patients attained complete remission (CR) while 20 showed disease progression during therapy or within 6 months after having reached CR; one patient relapsed. PET-2 was positive in 20 patients: 17 progressed during therapy, one relapsed and two remained in CR. By contrast, 85/88 (97%) patients with a negative PET-2 remained in CR; three progressed or relapsed early after the end of the chemotherapy. Thus, the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%. The sensitivity, specificity and overall accuracy of PET-2 were 86%, 98% and 95%, respectively. The 2-year probability of failure-free survival for PET-2 negative and for PET-2 positive patients was 96% and 6%, respectively (log rank test = 116.7, p18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients.
| Original language | English |
|---|---|
| Pages (from-to) | 475-481 |
| Number of pages | 7 |
| Journal | Haematologica |
| Volume | 91 |
| Issue number | 4 |
| Publication status | Published - Apr 2006 |
Fingerprint
Keywords
- Early response
- FDG-PET
- Hodgkin's disease
ASJC Scopus subject areas
- Hematology
Cite this
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. / Gallamini, Andrea; Rigacci, Luigi; Merli, Francesco; Nassi, Luca; Bosi, Alberto; Capodanno, Isabella; Luminari, Stefano; Vitolo, Umberto; Sancetta, Rosaria; Iannitto, Emilio; Trentin, Livio; Stelitano, Caterina; Tavera, Silvia; Biggi, Alberto; Castagnoli, Antonio; Versari, Annibale; Gregianin, Michele; Pelosi, Ettore; Torchio, Pierfederico; Levis, Alessandro.
In: Haematologica, Vol. 91, No. 4, 04.2006, p. 475-481.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
AU - Gallamini, Andrea
AU - Rigacci, Luigi
AU - Merli, Francesco
AU - Nassi, Luca
AU - Bosi, Alberto
AU - Capodanno, Isabella
AU - Luminari, Stefano
AU - Vitolo, Umberto
AU - Sancetta, Rosaria
AU - Iannitto, Emilio
AU - Trentin, Livio
AU - Stelitano, Caterina
AU - Tavera, Silvia
AU - Biggi, Alberto
AU - Castagnoli, Antonio
AU - Versari, Annibale
AU - Gregianin, Michele
AU - Pelosi, Ettore
AU - Torchio, Pierfederico
AU - Levis, Alessandro
PY - 2006/4
Y1 - 2006/4
N2 - Background and Objectives. We explored the predictive value on therapy outcome of an early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomography ( 18F-FDG-PET) scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease. Design and Methods. One hundred and eight patients with newly-diagnosed Hodgkin's disease in stage IIA with adverse prognostic factors, or in stage IIB through IVB, were re-staged with FDG-PET after two cycles of ABVD (PET-2). The end-point of the study was the predictive value of PET-2 on 2-year progression-free survival and 2-year failure-free survival. No treatment variation based only on PET-2 results was allowed. Results. Eighty-eight patients attained complete remission (CR) while 20 showed disease progression during therapy or within 6 months after having reached CR; one patient relapsed. PET-2 was positive in 20 patients: 17 progressed during therapy, one relapsed and two remained in CR. By contrast, 85/88 (97%) patients with a negative PET-2 remained in CR; three progressed or relapsed early after the end of the chemotherapy. Thus, the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%. The sensitivity, specificity and overall accuracy of PET-2 were 86%, 98% and 95%, respectively. The 2-year probability of failure-free survival for PET-2 negative and for PET-2 positive patients was 96% and 6%, respectively (log rank test = 116.7, p18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients.
AB - Background and Objectives. We explored the predictive value on therapy outcome of an early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomography ( 18F-FDG-PET) scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease. Design and Methods. One hundred and eight patients with newly-diagnosed Hodgkin's disease in stage IIA with adverse prognostic factors, or in stage IIB through IVB, were re-staged with FDG-PET after two cycles of ABVD (PET-2). The end-point of the study was the predictive value of PET-2 on 2-year progression-free survival and 2-year failure-free survival. No treatment variation based only on PET-2 results was allowed. Results. Eighty-eight patients attained complete remission (CR) while 20 showed disease progression during therapy or within 6 months after having reached CR; one patient relapsed. PET-2 was positive in 20 patients: 17 progressed during therapy, one relapsed and two remained in CR. By contrast, 85/88 (97%) patients with a negative PET-2 remained in CR; three progressed or relapsed early after the end of the chemotherapy. Thus, the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%. The sensitivity, specificity and overall accuracy of PET-2 were 86%, 98% and 95%, respectively. The 2-year probability of failure-free survival for PET-2 negative and for PET-2 positive patients was 96% and 6%, respectively (log rank test = 116.7, p18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients.
KW - Early response
KW - FDG-PET
KW - Hodgkin's disease
UR - http://www.scopus.com/inward/record.url?scp=33645998113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645998113&partnerID=8YFLogxK
M3 - Article
C2 - 16585014
AN - SCOPUS:33645998113
VL - 91
SP - 475
EP - 481
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 4
ER -